Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma

Caroline M. Woolston(University of Nottingham), Stewart G. Martin(University of Nottingham), Alexander M. Reece-Smith(Nottingham University Hospitals NHS Trust), Dileep N. Lobo(Nottingham University Hospitals NHS Trust), Irshad Soomro, Simon L. Parsons(Galapagos (Belgium)), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Redox Biology
January 1, 2013
10.1016/j.redox.2013.04.006
Cited by 28

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations
|World Journal of Surgery|2016|607
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374